{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"}]}],"title":"Grade 4 Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Grade 5 Event"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"29"}],"units":"Participants"}],"description":"Adverse Events: Incidence of adverse events, assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Adverse events were collected every cycle during treatment and up to one month after treatment. Adverse events were summarized using summary statistics and frequency tables for each separate cohort. Per protocol, analysis was descriptive in nature. In this section, the number of patients that reported a grade 4 or higher event are summarized. A complete listing of Adverse Events is provided in the Adverse Events section below.","groups":[{"description":"Liposarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Cohort 1"},{"description":"Leiomyosarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2"},{"description":"Undifferentiated Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Cohort 3"},{"description":"Malignant Peripheral Nerve Sheath Tumor patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG003","title":"Cohort 4"},{"description":"Other Sarcoma patients receive alisertib PO BID on days 1-7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.","id":"OG004","title":"Cohort 5"}],"paramType":"NUMBER","populationDescription":"All patients that began study treatment were assessed for this endpoint.","reportingStatus":"POSTED","timeFrame":"During treatment and up to 5 years","title":"Adverse Events","type":"SECONDARY","unitOfMeasure":"participants"}